The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Abstract
BACKGROUND: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear. METHODS: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF). The primary efficacy analysis compared the incidence of HIV infection in the lenacapavir group with the background HIV incidence in the screened population. The secondary efficacy analysis compared the incidence of HIV infection in the lenacapavir group with that in the F/TDF group. RESULTS: Among 3265 participants who were included in the modified intention-to-treat analysis, HIV infections occurred in 2 participants in the lenacapavir group (0.10 per 100 person-years; 95% confidence interval [CI], 0.01 to 0.37) and in 9 participants in the F/TDF group (0.93 per 100 person-years; 95% CI, 0.43 to 1.77). The background HIV incidence in the screened population (4634 participants) was 2.37 per 100 person-years (95% CI, 1.65 to 3.42). The incidence of HIV infection in the lenacapavir group was significantly lower than both the background incidence (incidence rate ratio, 0.04; 95% CI, 0.01 to 0.18; P<0.001) and the incidence in the F/TDF group (incidence rate ratio, 0.11; 95% CI, 0.02 to 0.51; P = 0.002). No safety concerns were identified. A total of 26 of 2183 participants (1.2%) in the lenacapavir group and 3 of 1088 (0.3%) in the F/TDF group discontinued the trial regimen because of injection-site reactions. CONCLUSIONS: The HIV incidence with twice-yearly lenacapavir was significantly lower than the background incidence and the incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 2 ClinicalTrials.gov number, NCT04925752.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Worldwide burden of HIV in transgender women: a systematic review and meta-analysis.
Baral, S. D., Poteat, T., Strömdahl, S., Wirtz, A. L., Guadamuz, T. E., & Beyrer, C. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70315-8 · Cited by 1,461
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., Cabello, R., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 900
Self-citationDelany-Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 586
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Bekker, L.-G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407001 · Cited by 523
Self-citationMayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428
Self-citationClinical targeting of HIV capsid protein with a long-acting small molecule
Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A., Hansen, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2443-1 · Cited by 425
Self-citationGlobal Epidemiology of HIV Infection and Related Syndemics Affecting Transgender People
Poteat, T., Scheim, A., Xavier, J., Reisner, S., & Baral, S. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001087 · Cited by 393
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Segal-Maurer, S., DeJesus, E., Stellbrink, H.-J., Castagna, A., Richmond, G. J., Sinclair, G. I., Siripassorn, K., Ruane, P. J., Berhe, M., Wang, H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115542 · Cited by 331
Self-citationCastillo-Mancilla, J. R., Zheng, J.-H., Rower, J. E., Meditz, A., Gardner, E. M., Predhomme, J., Fernandez, C., Langness, J., Kiser, J. J., Bushman, L. R., et al. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0089 · Cited by 315
Kanny, D., Jeffries, W. L., Chapin-Bardales, J., Denning, P., Cha, S., Finlayson, T., Wejnert, C., National HIV Behavioral Surveillance Study Group, National HIV Behavioral Surveillance Study Group, Abrego, M., et al. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6837a2 · Cited by 290
Cited by
Research progress on HIV-1 structural proteins and antiviral therapies
Wang, H., Yuan, J., & Wang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805597 · Cited by 2
“In parallel, vaccine-related approaches remain an important area of future development and are discussed further in the following section, particularly in the context of next-generation immunogen design and mRNA-based platforms (76, 125 – 127).”
Metadata
- Authors
- Kelley, C. F., Acevedo-Quiñones, M., Agwu, A. L., Avihingsanon, A., Benson, P., Blumenthal, J., Brinson, C., Brites, C., Cahn, P., Cantos, V. D., Clark, J., Clement, M., Creticos, C., Crofoot, G., Diaz, R. S., Doblecki-Lewis, S., Gallardo-Cartagena, J. A., Gaur, A., Grinsztejn, B., Hassler, S., Hinojosa, J. C., Hodge, T., Kaplan, R., Lacerda, M., LaMarca, A., Losso, M. H., Valdez Madruga, J., Mayer, K. H., Mills, A., Mounzer, K., Ndlovu, N., Novak, R. M., Perez Rios, A., Phanuphak, N., Ramgopal, M., Ruane, P. J., Sánchez, J., Santos, B., Schine, P., Schreibman, T., Spencer, L. Y., Van Gerwen, O. T., Vasconcelos, R., Vasquez, J. G., Zwane, Z., Cox, S., Deaton, C., Ebrahimi, R., Wong, P., Singh, R., Brown, L. B., Carter, C. C., Das, M., Baeten, J. M., & Ogbuagu, O.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-04-03
- Volume
- 392
- Issue
- 13
- Pages
- 1261-1276
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404784297
- Cited by
- 296
- References
- 31
- FWCI
- 93.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. https://app.cochat.ai/papers/10.1056/nejmoa2411858
- The paper
- Kelley, C. F., Acevedo-Quiñones, M., Agwu, A. L., Avihingsanon, A., Benson, P., Blumenthal, J., Brinson, C., Brites, C., Cahn, P., Cantos, V. D., Clark, J., Clement, M., Creticos, C., Crofoot, G., Diaz, R. S., Doblecki-Lewis, S., Gallardo-Cartagena, J. A., Gaur, A., Grinsztejn, B., . . . Ogbuagu, O. (2025). Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2411858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.